The FDA accepts Mercedon's update of Keytruda's dosing frequency

recently, Merck and Co announced that the U.S. Food and Drug Administration (FDA) has accepted six Supplemental Biologics Licenses (sBLA) to update the frequency of administration of Keytruda (Corida, Pabli pearl monoantitor) to include in the six-week (Q6W) dosing program.Specifically: every 6 weeks 400 mg intravenous infusion, infusion time is not less than 30 minutes, for Keytruda's 6 tumor adaptations: melanoma, classic Hodgkin lymphoma, primary vertical large B cell lymphoma, stomach cancer, hepatocellular cancer, Merkel cell carcinoma.About KeytrudaKeytruda is an anti-PD-1 tumor immunotherapy that helps detect and fight tumor cells by improving the body's immune system.Keytruda is an humanized monoclonal antibody that blocks the interaction between PD-1 and its hoses PD-L1 and PD-L2, activating T lymphocytes that may affect tumor cells and healthy cells.Currently, Keytruda's administration is 200mg (Q3W, intravenous infusions every 3 weeks for no less than 30 minutes). If approved, the Q6W solution will provide patients with a friendlier treatment option, less frequent dosing, and greater treatment flexibility for patients and oncologists.In the European Union, the Keytruda 400mg Q6W administration programme was approved on 28 March 2019 for all approved single-drug therapeutic adaptations covering eight of the five types of tumors, including non-small cell lung cancer (NSCLC), melanoma, bladder cancer, head and neck cancer, and classic Hodgkin's lymphoma. (Drug Information Network)